Long-term efficacy decreases by line of therapy and is linked with reduced survival1
In CML, for patients treated with a second line and a third line and those beyond TKI, the OS in 5 years decreased to 82% and 77%, respectively (p = 0.01).
Objective & Methods:
The main interest of this study was to assess the CML patient characteristics and outcome, especially the patient treated with more than two TKI lines, without access to new TKIs or experimental therapies.
Medical records were reviewed, from a retrospective cohort of 90 CML patients, diagnosed from January 2009, to October 2017.
All the patients were treated at Hospital de Clínicas de Porto Alegre (HCPA), Brazil. The analysis included patients in chronic phase (CP), accelerated phase (AP) and blast crisis (BC), followed for at least 12 months.
Pediatric patients (under 18 years old) and those treated with HSCT as second-line treatment were excluded from the analysis.
CML, Chronic myeloid leukemia; TKI, Tyrosine kinase inhibitor; OS, overall survival.
References
Bosi GR, Fogliatto LM, Costa TE, Grokoski KC, Pereira MP, Bugs N, Kalil M, Fraga C, Daudt LE, Silla LM. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?. Hematology, Transfusion and Cell Therapy. 2019 Oct 10;41:222-8.
Approved by Egyptian Drug Authority: HF0424OA5944/042026. Invalidation date: 20/04/2028
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
HF0424OA5944/042026 20/04/2028 |